Skip to main content

Table 2 Clinical profiles and ART status

From: Prevalence of malnutrition and its associated factors among adult people living with HIV/AIDS receiving anti-retroviral therapy at Butajira Hospital, southern Ethiopia

Variables    Frequency (n) Percent (%)
Eating difficulty No   235 77.0
Yes Problems 70 23.0
  Loss of appetite 63 20.7
  Vomiting 20 6.6
  Nausea 13 4.3
  Swallowing difficulty 6 2
Gastrointestinal symptoms No   255 83.6
Yes Problems 50 16.4
  Diarrhea 28 9.2
  Indigestion 22 7.2
  Constipation 7 2.7
WHO clinical stage Stage I   184 60.3
Stage II   54 17.7
Stage III   60 19.7
Stage IV   7 2.3
CD4+ T cell count <200 cells/μl   51 16.7
200–350 cells/μl   73 23.9
351–500 cells/μl   76 24.9
>500 cells/μl   105 34.4
Anemia status Normal   220 72.1
Anemic   85 27.9
Current/past OI in the past 6 months No   178 58.4
Yes Problems 127 41.6
  Acute/chronic diarrhea 45 14.8
  Tuberculosis 73 23.9
  Oral thrush 17 5.6
  Oral ulcer 8 2.6
  Pneumonia 8 2.6
  Zoster 3 1.0
  Pneumocystis carinii 1 0.3
ART regimens 1a (d4T + 3TC + NVP)   7 2.3
1c (AZT + 3TC + NVP)   122 40.0
1d (AZT + 3TC + EFV)   14 4.6
1e (TDF + 3TC + EFV)   132 43.3
1f (TDF + 3TC + NVP)   26 8.5
2b (TDF + 3TC + LPV/r)   4 1.3
Duration of ART <6 months   38 12.5
6–12 months   47 15.4
1–3 years   53 17.4
>3 years   167 54.8
Regimen change No   187 61.3
Yes   118 38.7
Reasons for change Toxicity/side effect   117 38.4
New tuberculosis   1 0.3
Drug adherence Good   277 90.8
Fair   20 6.6
  Poor   8 2.6
  1. Many patients were on stage I HIV status, one-third had CD4+ T cell count less than 500 cells/μl, and more than half of the patients had a history of opportunistic infection. Many of the patients took ART treatment for more than 3 years but had toxicity/side effect. However, drug adherences for many of the patients were good enough.
  2. AZT zidovudine, d4T stavudine, EFV efavirenz, NVP nevirapine, TDF tenofovir, 3TC lamivudine, LPV/r lopinavir + ritonavir.